These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 31748755)
1. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Gaffuri P; Espeli V; Fulciniti F; Paone G; Bergmann M Pathologica; 2019 Sep; 111(3):92-97. PubMed ID: 31748755 [TBL] [Abstract][Full Text] [Related]
2. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271 [TBL] [Abstract][Full Text] [Related]
3. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient. Vandepapelière J; Siplet J; Libbrecht L; Dano H; Baurain JF; Moreels T Acta Gastroenterol Belg; 2020; 83(3):482-484. PubMed ID: 33094598 [TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics and Outcomes of Pembrolizumab Induced Gastritis: A Systematic Review of the Literature. Lei H; Sun W; Liu X; Wang C J Gastrointest Cancer; 2024 Sep; 55(3):1-8. PubMed ID: 38787493 [TBL] [Abstract][Full Text] [Related]
5. Delayed hemorrhagic gastritis caused by immunotherapy in a patient With metastatic melanoma. Elmasry M; Dong B; Rios C; Breaux A; Miller D Am J Med Sci; 2022 Sep; 364(3):343-346. PubMed ID: 35276075 [TBL] [Abstract][Full Text] [Related]
6. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma. Kim H; Ha SY; Kim J; Kang M; Lee J Curr Oncol; 2020 Aug; 27(4):e436-e439. PubMed ID: 32905211 [TBL] [Abstract][Full Text] [Related]
8. A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. Lacey J; Lomax AJ; McNeil C; Marthick M; Levy D; Kao S; Nielsen T; Dhillon HM Support Care Cancer; 2019 Apr; 27(4):1497-1507. PubMed ID: 30392112 [TBL] [Abstract][Full Text] [Related]
9. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046 [TBL] [Abstract][Full Text] [Related]
10. Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab - Differences and Similarities in Comparison to "endogenous" autoimmune Type A Gastritis and a review of literature. Ecker ME; Weckauf H; Tebbe S; Schuppert F Z Gastroenterol; 2023 Oct; 61(10):1385-1393. PubMed ID: 36963423 [TBL] [Abstract][Full Text] [Related]
11. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Johncilla M; Grover S; Zhang X; Jain D; Srivastava A Histopathology; 2020 Mar; 76(4):531-539. PubMed ID: 31692018 [TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
13. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better. Atrash S; Makhoul I; Mizell JS; Hutchins L; Mahmoud F J Oncol Pharm Pract; 2017 Apr; 23(3):215-219. PubMed ID: 26811403 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895 [TBL] [Abstract][Full Text] [Related]
15. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma]. Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381 [TBL] [Abstract][Full Text] [Related]
16. Unusual severe gastritis and gastric ulcers caused by pembrolizumab. Liu WT; Li YF; Hsieh TY J Postgrad Med; 2022; 68(1):38-40. PubMed ID: 34121670 [TBL] [Abstract][Full Text] [Related]
17. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma. Roncati L Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488 [TBL] [Abstract][Full Text] [Related]
19. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia. Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S Eur J Cancer; 2019 May; 112():94-97. PubMed ID: 30954716 [No Abstract] [Full Text] [Related]
20. Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Levy D; Dhillon HM; Lomax A; Marthick M; McNeil C; Kao S; Lacey J Support Care Cancer; 2019 May; 27(5):1845-1852. PubMed ID: 30178142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]